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calcium pump 2, SERCA2) 
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Human embryonic stem cell 
Human induced pluripotent stem cell 
Induced pluripotent stem cell 
Inter-spike interval 
Potassium voltage-gated channel, Isk-related family, member 1 
Potassium voltage-gated channel, Isk-related family, member 2 
Potassium voltage-gated channel, subfamily H, member 2 (hERG) 
Potassium inwardly-rectifying channel, subfamily J, member 2 
Potassium voltage-gated channel, KQT-like subfamily, member 1 
Myosin, light chain 2, regulatory, cardiac, slow (MLC-2) 
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Abstract 
 
Introduction: Cardiac hypertrophy is a leading cause of many cardiovascular diseases, including 
heart failure, but its pathological mechanism is not fully understood. This study used highly purified 
human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes to produce an in vitro 
hypertrophy model and characterize its gene expression and electrophysiological properties. 
Methods: For 7 days we cultured hiPSC-derived cardiomyocytes plated at high (2800–4800 
cells/mm
2
) or low (500–1200 cells/mm2) cell density and assessed their cell size with confocal and 
fluorescence microscopy, their electrophysiological and pharmacological responses with 
multi-electrode array systems, and their gene expression patterns by using DNA microarray 
technology and quantitative PCR. We used quantitative PCR and Western blotting to compare the 
expression of potassium-channel genes between the hiPSC-derived cardiomyocytes and human fetal 
and adult hearts. 
Results: The hiPSC-derived cardiomyocytes showed spontaneous beating and similar pattern of 
α-actinin molecules regardless of plating density. However, cells plated at low density had the 
following characteristics compared with those at high density: 1) significant enlargement in size; 2) 
significant increase or decrease in expression of the cardiac hypertrophy-characteristic genes NPPA, 
ATP2A2, ANKRD1 and MYL2 in accordance with the progression of hypertrophy; 3) significant 
reduction in responses to the inhibitors of cardiac slow delayed-rectifier K
+
 current (IKs), chromanol 
293B and HMR1556, in a cell-density-dependent manner; and 4) significant reduction in the 
expression of the KCNQ1 and KCNJ2 genes coding the K
+
 ion channels conducting each IKs and 
cardiac inward rectifier outward K
+
 current (IK1). 
Discussion: The enlargement, hypertrophy-characteristic and potassium ion channels gene 
expression of hiPSC-derived cardiomyocytes suggest that low-density plating was sufficient to 
induce cardiac hypertrophy. This model may be useful in elucidating mechanisms underlying the 
onset and progress of cardiac hypertrophy, because these cells can be cultured for several weeks. 
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Introduction 
 
Pathological cardiac hypertrophy is defined as thickening of the ventricular wall and 
septum with a net decrease in ventricular chamber size occurring in response to pressure or volume 
stress or specific gene mutations. It often accompanies cardiovascular diseases such as hypertension, 
myocardial infarction, heart valve stenosis, and heart failure (Frey et al., 2004; Heineke & 
Molkentin, 2006). Although cardiac hypertrophy is generally a compensatory process in its initial 
stages, this process leads to cardiac fibrosis, congestive heart failure, arrhythmia, and sudden death 
if it is sustained long-term (Drazner et al., 2004; Vakili et al., 2001). During cardiac hypertrophy, 
because adult cardiomyocytes are terminally differentiated and have lost their ability to proliferate, 
they grow in size without cell division to cope with the escalating demand for increased workload 
due to pressure or volume stress or pathological conditions (Bernardo et al., 2010). 
Pathological cardiac hypertrophy models have been based on primary cultures of rat 
ventricular cardiomyocytes (Sadoshima et al., 1993; Shubeita et al., 1990). These cells increase in 
size in response to stimulation factors such as angiotensin II and endothelin 1 and demonstrate 
reactivation of the fetal cardiac gene program. An effective in vitro hypertrophy model using human 
cells would be useful for evaluating drugs for their causative or preventive effects on cardiac 
hypertrophy and for assessing cardiotoxic risk in patients with cardiac disorders. However, an 
opportunity of access to human cardiomyocytes for primary culture is limited and poorly amenable 
for this application. In contrast, human embryonic stem cell (hESC)- and human induced pluripotent 
stem cell (hiPSC)-derived cardiomyocytes recently became available and are likely in vitro tools for 
evaluating cardiotoxicity, including effects on cardiac hypertrophy, during drug development. When 
in a 3D cluster or a sheet, these cells show spontaneous and synchronized beating and respond to 
various ion-channel blockers, because they have many of the same ion channels that are expressed 
in native human cardiomyocytes (Ma et al., 2011; Yamazaki et al., 2012). In addition, hESC- and 
hiPSC-derived cardiomyocytes manifest features of hypertrophy under mechanical and chemical 
stress (Foldes et al., 2011; Tulloch et al., 2011). Compared with that in nonhuman-based models, the 
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hypertrophy induced in hESC- or hiPSC-derived cardiomyocytes likely will be more relevant to 
human cardiac hypertrophy. 
Patients with cardiac hypertrophy are at high risk of clinical complications such as 
progressive heart failure, arrhythmia, and sudden cardiac death (Maron, 2002; Maron et al., 2003). 
Dogs with chronic complete atrioventricular block can develop ventricular hypertrophy, and the 
incidence of early-after depolarization (EAD) can increase and torsades de pointes can be observed 
after treatment with a class III antiarrhythmic compound (Volders et al., 1998); the cardiac inward 
rectifier outward K
+
 current (IK1) and the rapid and slow components of the delayed-rectifier K
+
 
current (IKr and IKs) are reduced owing to electrical remodeling (Volders et al., 1999). In 
cardiomyocytes, oligomeric association of the potassium voltage-gated channel, KQT-like 
subfamily, member 1 (KCNQ1; α-subunit) and potassium voltage-gated channel, Isk-related family, 
member 1 (KCNE1; β-subunit) yields a potassium channel that carries the IKs (Melman et al., 2002). 
IKs is important for the repolarization of cardiac action potential, and decreases in IKs due to 
mutations in the KCNQ1 and KCNE1 genes cause long-QT syndrome (Harmer et al., 2010; Roden 
et al., 1996). Dogs with chronic atrioventricular block have consistently shown significant 
concurrent reduction in the density of IKs and KCNQ1 mRNA and protein levels (Ramakers et al., 
2003; Stengl et al., 2006), although these two studies have reported a decrease (Ramakers et al., 
2003), or no change (Stengl et al., 2006), in KCNE1 mRNA and protein levels with decreased IKs. 
Although right ventricular human cardiac cells with severe histological and functional abnormalities 
have demonstrated decreased IKs (Li et al., 2004), the expression levels of the KCNQ1 and KCNE1 
genes during cardiac hypertrophy have not yet been clarified. Hypertrophy models comprised of 
hiPSC-derived cardiomyocytes likely will be useful for exploring changes in these currents. 
In this study, we used hiPSC-derived cardiomyocytes to produce an in vitro human 
hypertrophy model. hiPSC-derived cardiomyocytes are non-dividing, beat spontaneously, express 
many cardiomyocyte-related genes, and are nearly pure cultures of cardiomyocytes (Anson et al., 
2011; Kattman et al., 2011). These characteristics differ from those of primary cultures of human 
cardiomyocytes, which contain fibroblasts (Ancey et al., 2003), and human fetal cardiomyocytes, 
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which proliferate (Erokhina et al., 2005). In addition, the multi-electrode array system has been 
used successfully to pharmacologically evaluate IKs blockers in hESC-derived and hiPSC-derived 
cardiomyocytes (Egashira et al., 2012; Yamazaki et al., 2012), further indicating the advantages of 
these cells over primary cardiomyocytes isolated from dogs, rabbits, and humans, which have low 
sensitivity to IKs blockers (Jost et al., 2005). Here, we used gene expression analysis and 
electrophysiological measurement by the multi-electrode array system to confirm the cell 
hypertrophy and the reduction of IKs in our hiPSC-derived cardiomyocytes. We found that these cells 
showed a hypertrophy-like phenotype under low-density culture conditions and decrease sensitivity 
to IKs blockers in electrophysiological assay. 
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Methods 
 
1. Cell and reagents 
As pre-culture, hiPSC-derived cardiomyocytes (iCell Cardiomyocytes, Cellular Dynamics 
International, Madison, WI, USA) were plated according to the manufacturer's protocol on gelatin 
(Sigma-Aldrich, St. Louis, MO, USA)-coated 6-well plates in iCell Cardiomyocyte Plating Medium 
(Cellular Dynamics International) at a density of 4.5 × 10
6
 to 6.0 × 10
6
 cells/well (that is, 4688–-
6250 cells/mm
2
) and incubated at 37 °C in 5% CO2 for 2 to 21 days. Every 2 days after plating, half 
of the volume of the medium was removed and replaced with iCell Cardiomyocytes Maintenance 
Medium (Cellular Dynamics International). 
For cell imaging, hiPSC-derived cardiomyocytes were isolated by treatment with 0.25% 
trypsin–EDTA (Sigma-Aldrich) after 2 days of pre-culture and re-plated on gelatin-coated 96-well 
glass-bottom plates in iCell Cardiomyocytes Maintenance Medium at a density of 90,000 cells/well 
(high density, 2813 cells/mm
2
) or 22,500 cells/well (low density, 703 cells/mm
2
) and incubated at 
37 °C in 5% CO2. Every 2 days after plating, half of the volume of the medium was removed and 
replaced with iCell Cardiomyocytes Maintenance Medium. After the cells had been cultured for 7 
days, they were fixed with 4% paraformaldehyde (Wako Pure Chemical Industries, Osaka, Japan) 
and washed in phosphate-buffered saline (PBS; Wako Pure Chemical Industries) for 
immunohistochemistry. Some cultures were left unfixed for confocal microscopy. 
For the extracellular field-potential recordings, hiPSC-derived cardiomyocytes were 
isolated by using 0.25% trypsin-EDTA after 6 to 21 days of pre-culture, and 2 μL of cell suspension 
was plated on a small area (that is, approximately 2 mm in diameter) coated with fibronectin (Life 
Technologies, Carlsbad, CA, USA) covering the area of electrodes (1.05 mm×1.05 mm) on MED64 
probes (MED-P515A, Alpha MED Sciences, Osaka, Japan) at a density of 30,000 cells/probe (very 
high density, 9554 cells/mm
2
), 15,000 cells/probe (high density, 4777 cells/mm
2
), 7500 cells/probe 
(medium density, 2389 cells/mm
2
) or 3750 cells/probe (low density, 1194 cells/mm
2
). Cell densities 
in cells/mm
2
 were calculated, assuming that the cells were plated in a circular area 2 mm in diameter. 
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Beginning 5 to 7 days after being plated on the electrodes, sheets of synchronously beating cells 
were subjected to field-potential recordings. 
For total RNA extraction, hiPSC-derived cardiomyocytes (without pre-culture) were plated 
on gelatin-coated 6-well plates in iCell Cardiomyocyte Plating Medium at a density of 2.7 × 10
6
 
cells/well (high density, 2813 cells/mm
2
) or 0.5 × 10
6
 cells/well (low density, 521 cells/mm
2
) and 
incubated at 37 °C in 5% CO2. Every 2 days after the plating, half of the volume of the medium was 
removed and replaced with iCell Cardiomyocytes Maintenance Medium. At 7 days after plating, 
cells were washed with PBS and lysed with RLT buffer (RNeasy Mini Kit, Qiagen, Hilden, 
Germany) containing 1% 2-mercaptoethanol (Nacalai Tesque, Kyoto, Japan). 
For protein extraction, hiPSC-derived cardiomyocytes (without pre-culture) were plated on 
gelatin-coated 24-well plates in iCell Cardiomyocyte Plating Medium at a density of 5.3 × 10
5
 
cells/well (high density, 2819 cells/mm
2
) or 98,000 cells/well (low density, 521 cells/mm
2
) and 
incubated at 37 °C in 5% CO2. Every 2 days after plating, half of the volume of the medium was 
removed and replaced with iCell Cardiomyocytes Maintenance Medium. Seven days after plating, 
cells were washed with PBS, trypsinized, and counted under a microscope. After the cell count, 
cells were lysed with RIPA buffer (Thermo Fisher Scientific, Waltham, MA, USA) containing 
protease inhibitors (Complete, Roche Diagnostics, Mannheim, Germany). 
 
2 Confocal fluorescence microscopy 
hiPSC-derived cardiomyocytes were stained with CellMask Plasma Membrane Deep Red 
(dilution, 1:1000; Life Technologies) for 30 min at 37 °C in 5% CO2. Confocal images were 
acquired by using a confocal fluorescence microscope (LSM 510 META, ZEISS, Oberkochen, 
Germany) with a 63× objective. The total area of cells was determined by using the area 
measurement tool of ImageJ software (version 1.46, freeware program of National Institutes of 
Health, USA; http://rsbweb.nih.gov/ij/). Statistical significance was calculated by using Welch’s 
t-test (Prism 6, GraphPad Software, La Jolla, CA, USA). 
 
 9 
3 Immunocytochemistry 
hiPSC-derived cardiomyocytes after fixed in 4% paraformaldehyde permeabilized by 
being treated for 30 min with Tris-buffered saline (TBS; Bio-Rad Laboratories, Hercules, CA, USA) 
containing 0.1% Triton X-100 (Wako Pure Chemical Industries), and blocked with 4% Block Ace 
(DS Pharma Biomedical, Osaka, Japan) for 60 min. The hiPSC-derived cardiomyocytes were 
stained with anti-α-actinin antibody (dilution, 1:1000; Sigma-Aldrich) overnight at room 
temperature, washed three times with TBS containing 0.05% Tween 20 (TBS-T; Bio-Rad 
Laboratories), and then stained with Alexa Fluor 488 Donkey Anti-Mouse IgG (H+L) (1:500; Life 
Technologies), CellMask Deep Red (1:5000; Life Technologies), and Hoechst 33342 (1:100; 
Sigma-Aldrich) for 30 min. After being stained, hiPSC-derived cardiomyocytes were washed three 
times with TBS-T and viewed under a fluorescence microscope (IX81; Olympus, Tokyo, Japan) 
with a 20× objective. 
 
4. Extracellular field-potential recordings  
The extracellular field potential of sheet cells was recorded by using the MED64 System 
(Alpha MED Sciences) and its accompanying software (Mobius QT, Alpha MED Sciences) 
according to previous report (Yamazaki et al., 2012). Briefly, the field potential duration (FPD) 
regarded as a QT-like interval in electrocardiogram was defined as the interval from the initial sharp 
deflection to the later peak of positive or negative deflection in waveforms. Output signals were 
digitized at 20 kHz. In addition, beat frequencies and inter-spike intervals (ISIs) were recorded. 
Thirty minutes before the start of field potential measurement, the culture medium was replaced 
with fresh iCell Cardiomyocytes Maintenance Medium pre-warmed to 37 °C. After equilibration, 
the preparations were placed on a hot plate and kept at 37 °C; they were covered with a lid through 
which aeration of 95% O2, 5% CO2 gas was provided. Before the addition of vehicle or a compound 
to the medium, waveforms and the regularity of the beating rates and FPDs were checked for more 
than 30 min. Compound solutions were added cumulatively to the medium at one-thousandth 
volume (2 μL). After the addition of compound, the medium was mixed by careful pipetting. 
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Compounds tested were the IKs blockers Chromanol 293B (1, 3, 10 and 30 μM; Sigma-Aldrich) and 
HMR1556 (0.1, 0.3, 1 and 3 μM; synthesized by Eisai Co., Ltd.) and the IKr blocker E4031 (0.3, 1, 3, 
10 and 30 nM; Wako Pure Chemical Industries), which were dissolved in dimethyl sulfoxide 
(DMSO; Wako Pure Chemical Industries). Baseline for each compound was measured by addition 
of 2 μL DMSO. In previous report, we confirmed that the cumulative sixth addition of 2 μL DMSO 
did not affect the FPD (Yamazaki et al., 2012). The FPD for the baseline and each concentration of 
a compound was measured for 10 min, near the end of which time we extracted 30 FPDs and ISIs 
for analysis. A corrected FPD (FPDc) was calculated according to Fridericia’s formula (FPDc = 
FPD/ISI
1/3
), and the 30 FPDc values were averaged. The prolongations of FPDc were almost the 
same between shortest (6 days) and longest (21 days) pre-culture for the response to HMR1556 and 
E4031 in high-density-cultured cells in this study. The % FPDcs to control in 6 or 21 
days-pre-cultured cells were 136.09% (n = 6) and 134.12% (n = 2) with HMR1556 (3 µM), and 
121.91% (n = 2) and 134.72% (n = 2) with E4031 (30 nM), respectively. Therefore, all the data for 
different pre-culture conditions were pooled for analysis. Statistical significance was calculated by 
using t-tests for unpaired unequal variance (Welch’s t-test) in Prism 6 (GraphPad Software) to 
compare FPD, ISI and FPDc values between different density cells, and the Jonckheere-Terpstra 
trend test (Jonckheere, 1954; Terpstra, 1952) in the R 2.15.2 using SAGx package 
(http://www.R-project.org/; http://www.bioconductor.org/packages/release/bioc/html/SAGx.html) to 
show cell-density-dependent effects on FPDc. 
 
5. RNA extraction 
Total RNA was prepared from hiPSC-derived cardiomyocytes by using RNeasy mini spin 
columns (Qiagen) according to the manufacturer’s protocol. The yield and quality of each isolated 
total RNA sample was determined by using a NanoDrop 1000 spectrophotometer (Thermo Fisher 
Scientific) and RNA Nano LabChips analyzed on a 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA, USA). NanoDrop spectrophotometers measure absorbency at wavelengths of 280 nm 
and 260 nm; ratios of these absorbencies (that is, A260:A280) are used to assess sample purity. An 
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A260:A280 ratio of approximately 2.0 is considered pure for RNA samples. The 2100 Bioanalyzer 
obtains the RNA Integrity Number (RIN) from the pattern of total RNA electrophoresed as a metric 
for RNA degradation (Schroeder et al., 2006). A RIN of 9.5–10.0 is considered pure for total RNA 
from the hiPSC-derived cardiomyocytes. 
 
6. Total RNA from human fetal and adult hearts 
Human adult-heart total RNA were obtained from 3 vendors: 1) Human Heart Total RNA 
(lot# 1112059A, Clontech, Mountain View, CA, USA); 2) Total RNA, Human Heart (lot# 
0006097996, Agilent Technologies); and 3) Total RNA—Human Adult Normal Tissue, Heart (lot# 
B604038, BioChain, Newark, CA, USA). In addition, human fetal-heart total RNA were obtained 
from 3 vendors: 1) Human Fetal Heart Total RNA (lot# 1005013, Clontech); 2) Total RNA, Human 
Fetal Heart (lot# 0006111328, Agilent Technologies); and 3) Total RNA—Human Fetal Normal 
Tissue, Heart (lot# B512117, BioChain). 
 
7. Microarray analysis 
100 ng total RNA was converted to cyanine-3 (Cy3)-labeled complementary RNA (cRNA) 
by using a Low Input Quick Amp Labeling Kit, One-Color (Agilent Technologies) according to the 
manufacturer’s instructions for single-color 8×60K gene expression arrays. Cy3-labeled cRNAs 
were purified by using an RNeasy Mini purification kit (Qiagen) and hybridized to the SurePrint G3 
Human Gene Expression 8×60K Microarray (Agilent Technologies) at 65 °C for 17 h by using a 
Gene Expression Hybridization Kit (Agilent Technologies) according to the manufacturer’s 
instructions. Arrays were washed with a Gene Expression Wash Pack (Agilent Technologies) and 
scanned on a DNA Microarray Scanner (Agilent Technologies) according to the manufacturer’s 
instructions. Quantification of scanned images was accomplished by using Feature Extraction 
software (version 11, Agilent Technologies). The resulting files were imported and analyzed with 
GeneSpring (version 12.5, Agilent Technologies). Raw data were normalized by using a quantile 
method. The P-values for all statistical tests were estimated by using Welch’s t-test, followed by 
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adjustment for multiple comparisons by using the false-discovery rate (FDR) approach 
(Benjamini-Hochberg procedure). A gene was considered to be differentially expressed when its 
absolute fold change relative to the control value was ≥1.5 with an FDR P-value of ≤0.05. Pathway 
analysis was conducted by using Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, 
CA, USA). 
 
8. Quantitative real-time RT-PCR analysis 
The cDNA synthesis was run in 10-μL volumes containing 500 ng total RNA by using a 
High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Life Technologies) 
according to the manufacturer’s instructions. Quantitative PCR analysis of 7.2 ng cDNA (total RNA 
equivalent) per well in duplicate (n = 3 biological replicates) by using TaqMan Fast Advanced 
Master Mix (Life Technologies) on a ViiA7 Real-time PCR System (Life Technologies) was 
performed. TaqMan Gene Expression Assays were purchased from Life Technologies; KCNQ1: 
Hs00923522_m1; KCNE1: Hs00897540_s1; KCNE2: Hs00270822_s1; KCNH2: Hs00165120_m1; 
KCNJ2: Hs00265315_m1; NPPA: Hs00383231_m1; ATP2A2: Hs00155939_m1; ANKRD1: 
Hs00173317_m1; MYL2: Hs00166405_m1; GAPDH (glyceraldehyde-3-phosphate dehydrogenase): 
Hs99999905_m1; 18S rRNA (Eukaryotic 18S ribosomal RNA): Hs99999901_s1 and ACTB (actin, 
beta): Hs99999903_m1. Cycle threshold (Ct) values were determined by using ViiA7 software 
version 1.1 (Life Technologies). A 6-point standard curve was used to determine PCR efficiency and 
relative quantitation. Relative gene expression normalized against the expression level of 18S rRNA 
was calculated by using Excel 2010 (Microsoft, Redmond, WA, USA). Statistical significance was 
calculated by using Welch’s t-test in Prism 6. 
 
9. Protein extraction and Western blotting 
Whole-cell lysates were prepared from hiPSC-derived cardiomyocytes by using RIPA 
buffer (Thermo Fisher Scientific) containing protease inhibitors (Complete, Roche Diagnostics), in 
accordance with each manufacturer’s protocol. The protein concentration of each lysate was 
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determined by using a Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) and a SpectraMax 
190 (Molecular Devices, Sunnyvale, CA, USA) with SoftMax Pro software (version 5.2, 
4-parameter mode, Molecular Devices). Statistical significance was analyzed by using Welch’s t-test 
(Prism 6). 
The volume of lysate containing 10 μg of protein samples was denatured with Laemmli 
Sample Buffer (Bio-Rad Laboratories) containing 2.5% 2-mercaptoethanol, fractionated by 
SDS-PAGE on 5%–20% polyacrylamide gels (e-PAGEL, ATTO, Tokyo, Japan) with a Spectra 
Multicolor High Range Protein Ladder (Thermo Fisher Scientific), and then transferred 
electrophoretically to polyvinylidene difluoride membranes, with Tris–Glycine buffer (Bio-Rad 
Laboratories) containing 20% methanol (Wako Pure Chemical Industries) as the transfer buffer. 
Membranes were blocked in TBS-T containing 5% skim milk (Wako Pure Chemical Industries) and 
incubated overnight at 4 °C with primary antibodies (anti-KCNQ1 antibody, 1:200, Santa Cruz 
Biotechnology, Dallas, TX, USA; anti-KCNH2, 1:400, Alomone Labs, Jerusalem, Israel) in TBS-T 
containing 1% skim milk. After being washed, membranes were incubated with horseradish 
peroxidase–conjugated anti-rabbit IgG secondary antibody (1:5000, Cell Signaling Technology, 
Danvers, MA, USA). Antibody was detected by using Amersham ECL Prime Western Blotting 
Detection Reagent (GE Healthcare, Buckinghamshire, UK) on a luminescent image analyzer 
(LAS-4000 IR, FUJIFILM, Tokyo, Japan/GE Healthcare). Scanned images were quantified and 
expressed in arbitrary unit by using MultiGauge software (version 3.0, FUJIFILM). Statistical 
significance was calculated by using Welch’s t-test in Prism 6. 
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Results 
 
1. Low-density cell plating leads to enlargement of hiPSC-derived cardiomyocytes 
To evaluate the morphology of hiPSC-derived cardiomyocytes plated at high (90,000 
cells/well) and low (22,500 cells/well) densities and cultured on 96-well plates for 7 days, images of 
living cells were obtained by confocal fluorescence microscopy. In the high-density cultures the 
cells were round or polygonal, and most had a diameter of less than 50 μm. In contrast, the picture 
of microscopy showed much larger cells in the low-density cultures than those in high-density 
cultures; some cells at low density were longer than 100 μm in longitudinal length (Fig. 1A). Cell 
heights were less than 10 µm and did not differ between low- and high-density cultures (Fig. 1A). 
Cell area in low-density cultures was significantly increased compared with that of cells at high 
density (cell area in high- and low-density cultures, 711.88 and 1654.44 μm2; P ≤ 0.001, Fig. 1B). 
hiPSC-derived cardiomyocytes plated at low density stained positively with α-actinin, with staining 
distributed evenly throughout the cells and similar to that of cells plated at high density (Fig. 1C). 
The concentration of protein was measured in hiPSC-derived cardiomyocytes plated at high (5.3 × 
10
5
 cells/well) and low (98,000 cells/well) densities and cultured on 24-well plates for 7 days. 
Protein amount per single cell was significantly greater in cells at low than at high density (protein 
amount in high- and low-density cultures, 0.42 and 0.65 ng/cell, P ≤ 0.05, Fig. 1D). 
 
2. Gene expression analysis reveals similarities between low-density cultured hiPSC-derived 
cardiomyocytes and cardiac hypertrophy 
We performed DNA microarray analysis to examine differences in gene expression levels 
between cardiomyocytes grown under high- and low-density culture conditions, respectively. 
Pathway analysis was conducted by using the Tox Functions program of Ingenuity Pathway 
Analysis software and the list of gene probes in low-density cultured cells that showed a fold 
change (FC) of ≥1.5 and an FDR P-value of ≤0.05 compared with expression levels in high-density 
cultured cells. The list included 2370 and 2072 probes for genes with increased and decreased 
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expression, respectively (data not shown). Table 1 shows the top 10 toxicological functions that 
showed significant relationship with the gene list. All of the top 4 toxicological 
functions—hypertrophy of heart chamber, hypertrophy of heart, hypertrophy of left ventricle and 
ventricular hypertrophy—were members of the cardiac hypertrophy category. Figure 2A shows the 
expression of 3 housekeeping genes, GAPDH (glyceraldehyde-3-phosphate dehydrogenase), ACTB 
(actin, beta), and 18S rRNA (Eukaryotic 18S ribosomal RNA) in high- and low-density-cultured 
hiPSC-derived cardiomyocytes, fetal and adult heart. The expression level of GAPDH gene was 
significantly greater in high- and low-density hiPSC-derived cardiomyocytes than in human fetal 
and adult hearts (expression value of GAPDH in high- and low-density cells, fetal and adult hearts, 
1917.59, 1551.12, 856.45 and 738.82, respectively) and ACTB gene was significantly greater in 
low-density than in high-density hiPSC-derived cardiomyocytes and human fetal heart (ACTB in 
high- and low-density cells and fetal and adult hearts, 1294.97, 2627.65, 1350.34 and 1622.15, 
respectively). In contrast, 18S rRNA was not altered among all samples. We selected 18S rRNA as 
the normalizer for later qPCR analysis because it was expressed invariably in all types of the RNA 
samples used in this study. The expression of genes associated with cardiac hypertrophy, including 
NPPA (natriuretic peptide A/atrial natriuretic peptide, ANP), ATP2A2 (ATPase, Ca
2+
 transporting, 
cardiac muscle, slow twitch 2/sarcoplasmic reticulum calcium pump 2, SERCA2), ANKRD1 
(ankyrin repeat domain 1, cardiac muscle/cardiac ankyrin repeat protein, CARP), and MYL2 
(myosin, light chain 2, regulatory, cardiac, slow/MLC-2) (Aihara et al. 2000; Ju et al. 1996; 
Sadoshima et al. 1993; Shubeita et al. 1990) was shown in Figure 2B. NPPA, ANKRD1 and MYL2 
expression was greater, and ATP2A2 expression less, in the low-density cultured hiPSC-derived 
cardiomyocytes than in the high-density cultured cells (relative expression values: NPPA, 0.26 and 
1.59, respectively, P ≤ 0.01; ATP2A2, 1.39 and 0.94, respectively, P ≤ 0.05; ANKRD1, 1.00 and 1.56, 
respectively, P ≤ 0.01; MYL2, 0.72 and 1.22, respectively, P ≤ 0.01). The directions of the 
expression-level changes were consistent with progression to pathologic hypertrophy. 
 
3. Low-density cultured hiPSC-derived cardiomyocytes have decreased sensitivity to IKs 
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blockers  
We evaluated the effects of IKs and IKr blockers on FPDc in hiPSC-derived cardiomyocytes 
plated at densities of 30,000 (very high density), 15,000 (high density), 7500 (medium density), and 
3750 (low density) cells/probe. The success rate of field-potential recording decreased as cell 
density was reduced, and fewer data were obtained from cells plated at low density. Fig. 3 shows 
the basal FPD, ISI and FPDc at different cell densities. FPD, ISI and FPDc at low density were 
significantly greater than those at very-high-density (FPD, ISI and FPDc in very high- and 
low-density cultures, 270.04 and 306.17 msec, P ≤ 0.001; 773.59 and 876.71 msec, P ≤ 0.05; and 
295.05 and 320.43 msec, P ≤ 0.01, respectively). FPDc was prolonged by the IKs blockers 
chromanol 293B and HMR1556 and by the IKr blocker E4031 in a concentration-dependent manner 
above 3 μM, 0.3 μM, and 3 nM, respectively, at all cell densities (Fig. 4A). In addition, the slopes of 
FPDc prolongation decreased in a cell density-dependent manner with chromanol 293B and 
HMR1556. The prolongation of FPDc with chromanol 293B was 126.65%, 124.21%, and 118.92% 
at a concentration of 30 μM in cultures of very high, high, and medium cell densities, respectively, 
and had a significant trend between decrease of cell density and decrease of FPDc prolongation (P ≤ 
0.05). With HMR1556, the prolongation at 1 μM was 125.13%, 123.32%, 121.13% and 115.01%, 
and at 3 μM was 132.57%, 124.94%, 122.94% and 113.99% in cultures of very high, high, medium, 
and low cell densities, respectively, and had a significant trend between decrease of cell density and 
decrease of FPDc prolongation (P ≤ 0.05 and P ≤ 0.001, respectively). In contrast to the responses 
to IKs blockers, there was no significant difference in the increases in FPDcs at very high, high, 
medium, and low cell densities with E4031 at 30 nM (FPDc prolongation was 119.10%, 115.72%, 
110.87% and 133.09%, respectively), but low-density cells showed greater prolongation of FPDcs 
with statistical significance (P ≤ 0.05 or P ≤ 0.01) compared with other densities. Two in 5 
preparations at low density showed waveforms of early after depolarization (Fig. 4B), and were not 
included in the analysis of FPDc. 
 
4. Expression of genes associated with potassium channels, including IKs channel subunits, in 
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hypertrophic phenotypes of low-density cultured hiPSC-derived cardiomyocytes 
To examine changes in potassium channels of the low-density cultured hiPSC-derived 
cardiomyocytes, we used quantitative PCR analysis to measure the expression levels of the KCNQ1, 
KCNE1, KCNE2, KCNH2 (potassium voltage-gated channel, subfamily H, member 2/hERG), and 
KCNJ2 (potassium inwardly rectifying channel, subfamily J, member 2) genes. The expression 
levels of these genes in the hiPSC-derived cardiomyocytes at 2.7 × 10
6
 cells/well (high density) or 
0.5 × 10
6
 cells/well (low density) were compared with those of human fetal and adult hearts. 
Expression of KCNQ1 was decreased (relative expression value of KCNQ1 in high- and low-density 
cells, 1.66 and 1.14, respectively, P ≤ 0.05), but that of KCNE1 was upregulated (KCNE1 in high- 
and low-density cells, 0.88 and 2.40, respectively, P ≤ 0.001) in hiPSC-derived cardiomyocytes 
plated at low density compared with those at high density (Fig. 5A). In addition, expression of 
KCNJ2, which conducts IK1 current, was downregulated (KCNJ2 in high- and low-density cells, 
0.41 and 0.17, respectively, P ≤ 0.001) in low-density cells compared with those in high-density 
cells (Fig. 5A). Expression of KCNQ1, KCNH2 and KCNE2 was significantly greater in high- and 
low-density hiPSC-derived cardiomyocytes than in human fetal and adult hearts (KCNQ1 in high- 
and low-density cells, fetal and adult hearts, 1.66, 1.14, 0.90 and 0.74, respectively; KCNH2, 1.66, 
2.02, 0.56 and 0.63; KCNE2, 1.68, 1.29, 0.50 and 0.24). Expression of KCNE1 in low-density cells 
was greater than in human adult heart (low-density cells and adult heart, 2.40 and 1.34, P ≤ 0.05) 
but was equivalent between low-density cells and human fetal heart (Fig. 5A). The protein level of 
KCNQ1 was lower in low-density than in high-density cells (intensity of KCNQ1 protein band in 
high- and low-density cells, 8212822.29 and 4775372.12, respectively, P ≤ 0.05) (Fig. 5B and 5C). 
The protein level of KCNH2 was equivalent between high- and low-density cells (Fig. 5B and 5C). 
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Discussion 
 
We found here that hiPSC-derived cardiomyocytes showed a hypertrophy-like phenotype 
only after the cells were exposed to low-density culture conditions and that the expression levels of 
cardiac hypertrophy-related genes in low-density hiPSC-derived cardiomyocytes were altered in 
accordance with disease progression. Cardiac hypertrophy is a leading cause of many 
cardiovascular diseases and a key cause of heart failure (Drazner et al., 2004; Frey et al., 2004; 
Heineke & Molkentin, 2006; Vakili et al., 2001). Because hypertrophic hearts may be highly 
sensitive to the toxic effects of drugs, evaluating candidate new compounds in this model of cardiac 
hypertrophy may prove valuable. 
One of the characteristic features of cardiac hypertrophy is the enlargement of 
cardiomyocytes; an approximate 1.5 times the size of cardiomyocytes has been reported in in vitro 
and in vivo studies of dogs, rats, and rabbits (Flores-Munoz et al., 2012; Hao et al., 2007; Volders et 
al., 1998; Zou et al., 2006). In our model, cells in low-density cultures were 2.4 times larger on 
average than were those in high-density cultures, according to the average size of high-density 
cultures without factoring in changes in cell height. Some cells in low-density cultures were more 
than 5 times larger than were those plated at high density. This marked enlargement of 
hiPSC-derived cardiomyocytes may reflect the large extracellular space in low-density cell plating 
compared with the limited space for expansion in in vivo studies. Another possible explanation for 
the marked cell enlargement is the small size of the cardiomyocytes (including hiPSC-derived 
cardiomyocytes) at early developmental stages, as stem-cell-derived cardiomyocytes do not as yet 
developed as adult cardiomyocytes (Khan et al., 2013) and can grow greatly in size during postnatal 
development to adult size in the absence of proliferation. In hypertrophic models using neonatal rat 
cardiomyocytes (Watkins et al., 2011) or human stem-cell-derived cardiomyocytes (Foldes et al., 
2011), a doubling in cell size over 2 days was observed. The greater enlargement of the 
hiPSC-derived cardiomyocytes here than in previous studies may be related to the duration of 
culture (7 days) at low density. Increased protein synthesis has been reported as another feature of 
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hypertrophy (Bernardo et al., 2010) and supports that of the low-density cultured hiPSC-derived 
cardiomyocytes. Even though they are greatly enlarged, the function of the cells seems to be normal, 
because the low-density cultured hiPSC-derived cardiomyocytes beat spontaneously (data not 
shown) and because staining for sarcomeric cardiac actinin (α-actinin) was distributed similarly 
throughout the cells regardless of plating density. 
Pathological cardiac hypertrophy is due to responses to a stimulation factor, such as 
angiotensin II or endothelin 1, and shows a phenotype of hypertrophic growth characterized by 
increased cell size and expression of fetal cardiac genes (e.g., NPPA, ATP2A2, ANKRD1 and MYL2) 
to compensate for reduced cardiac function (Aihara et al., 2000; Ju et al., 1996; Sadoshima et al., 
1993; Shubeita et al., 1990). The expression levels of NPPA, ATP2A2, ANKRD1 and MYL2 in the 
low-density cultured hiPSC-derived cardiomyocytes were similar to those in previous reports 
(Aihara et al., 2000; Ju et al., 1996; Sadoshima et al., 1993; Shubeita et al., 1990), showing 
progression toward pathology in these cells. Furthermore, our pathway analysis using Ingenuity 
Pathway Analysis software supported our claim that the low-density cultured hiPSC-derived 
cardiomyocytes had a hypertrophic phenotype. In addition, reduction of KCNQ1 gene expression 
was in line with a report that IKs and KCNQ1 gene expression were reduced in a cardiac hypertrophy 
model (Ramakers et al., 2003; Stengl et al., 2006; Volders et al., 1999). We feel that these combined 
results indicate that the enlarged hiPSC-derived cardiomyocytes after low-density culture are 
effective models of hypertrophied cardiac cells, even though specific manipulations, such as 
pharmacological treatment to induce hypertrophy, were not used. 
Several possibilities regarding the mechanisms of induction of hypertrophy in the 
cardiomyocytes here need to be considered. First, the extracellular coating materials may have 
caused the observed cardiac hypertrophy, given that fibronectin (but not gelatin) induces cardiac 
hypertrophy in in vitro rat models (Chen et al., 2004; Ogawa et al., 2000). We were able to observe 
enlargement of cells using either gelatin or fibronectin, suggesting that the coating material may not 
be the key cause of hypertrophy. In addition, if the coating material had been the sole cause of the 
change in gene expression, then similar changes likely would have occurred in low- and 
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high-density cultures. Second, the attachment of the cells to the plate surface might have initiated 
signals to promote hypertrophy. If this were the case, the signals would have increased in intensity 
as the cells plated at low density and enlarged until they contacted other cells. However, these 
signals likely do not occur in high-density cultures, because the cells were densely seeded and 
contacted other cells from the onset. Third, some component(s) of the culture medium might have 
contributed to the induction of hypertrophy. The exact factors that induce hypertrophy in 
cardiomyocytes have not yet been clarified, but it will be interesting to explore the mechanism(s) to 
gain insights into hypertrophy. 
Electrical remodeling in hypertrophied cardiomyocytes is well characterized, and changes 
in expression levels of various ion channels underlie this phenomenon. In dog cardiac hypertrophy, 
prolongation of action potential duration and downregulation of sarcolemmal K+ currents, including 
IKs (Volders et al., 1998; 1999), has been reported. Here, we did not measure the level of IKs by 
using patch-clamp experiments, but the increase in FPD/FPDc, the decreased sensitivity to IKs 
blockers and the reduction of KCNQ1 gene expression in low-density cultured cardiomyocytes may 
indicate a decrease in IKs current in these cells. The decrease in KCNQ1 protein expression in 
Western blot analysis also supported this possibility, but there is uncertainty in the plasma 
membrane expression level of KCNQ1 channels. Since the increase in cell surface area is 
theoretically less than that of cell volume, the reduction of KCNQ1 protein level in whole cell lysate 
might not have caused the reduction of density of KCNQ1 channel in plasma membrane. This point 
remains to be clarified yet in future by using a membrane fraction. We suggest that the significant 
prolongation of FPD, ISI, and FPDc in low-density cells is due to changes in the expression of ion 
channels that contribute to action potential repolarization. However, the significant prolongation of 
basal FPDc in high-density (15,000 cells/probe) cultures is not likely a result of this same 
mechanism, because FPD and ISI were similar among high-, very high-, and middle-density (30,000 
and 7500 cells/probe) cultures of cells. From a different viewpoint, the method used to correct FPD 
against ISI, Fridericia’s formula (FPDc = FPD/ISI1/3), may have caused this phenomenon. The 
action potential duration corresponding to FPD changes with alterations in the preceding interval of 
 21 
excitation; therefore, FPD must be corrected by using some formula to compare the change on the 
basis of the same ISI. Because hiPSC-derived cardiomyocytes beat at around 60 bpm, we used 
Fridericia’s formula, which typically is used for correction of the human QT interval 
(Funck-Brentano and Jaillon, 1993). However, this correction formula may not be optimal for 
hiPSC-derived cardiomyocytes and therefore may induce error into the correction. IKs current can 
contribute to the repolarization of cardiac action potentials but generally functions as a 
repolarization reserve. Therefore, in the basal state, inhibition of IKs current will not cause a notable 
change in action potential duration, but native cardiomyocytes activated through β-receptor 
stimulation demonstrate increased action potential duration by inhibition of IKs current (Volders et 
al., 2003). In hiPSC-derived cardiomyocytes, the prolongation of FPDc by IKs blockade by 
inhibitors suggests that the IKs current contributed to the repolarization of action potentials in 
cardiomyocytes at high density plating. Prolongation of FPDc by chromanol 293B and HMR1556 
occurred at concentrations higher than 3 and 0.3 µM, respectively—higher than their respective 
reported IC50s. The IC50 values of chromanol 293B and HMR1556 in in vitro voltage-clamp 
experiments in dog primary cardiomyocytes and artificial KCNQ1 and KCNE1-overexpressed cells 
have been reported to be 1.8–15.4 µM and 10.5–34 nM, respectively (Taniguchi et al., 2012; 
Thomas et al., 2003). The two following hypotheses may explain these differences in concentration. 
The first hypothesis is that the actual free concentrations of these agents in our experiments are 
lower than the nominal concentrations, because the assay medium for FPD measurement contained 
serum, and the binding of these compounds to proteins may have decreased the free concentration. 
The plasma protein binding ratio of HMR1556 is reported to be 75% (Nakashima et al., 2004), 
suggesting that the unbound concentrations of blockers might have been lower than the nominal 
concentration in the previous study (Taniguchi et al., 2012; Thomas et al., 2003). Because the main 
structure of chromanol 293B is the same as that of HMR1556 (Gogelein et al., 2000), putative 
protein-binding of chromanol 293B with a subsequent decrease in its free concentration is similarly 
possible. It may be possible to confirm this hypothesis if an appropriate serum-free medium 
becomes available. A second hypothesis for the differing concentrations of HMR1556 and 
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chromanol 293B between studies is that the contribution of IKr to FPD is far greater than that of IKs 
in the hiPSC-derived cardiomyocytes, so that increased concentrations of IKs blockers are needed to 
demonstrate effects. Moreover, our data on the effects of IKs and IKr channel blockers for FPDc 
measurement in hiPSC-derived cardiomyocytes corresponded to those from previous other reports 
using hiPSC- or hESC-derived cardiomyocytes treated with chromanol 293B (3–30 µM) or 
HMR1556 (1–3 µM) (Ma et al., 2011; Yamazaki et al., 2012). Therefore, we think that the 
decreased sensitivity of low-density cultured hiPSC-derived cardiomyocytes to FPDc prolongation 
after the application of IKs blockers can be interpreted as the presence of less IKs current compared 
with that in high-density cells. The induction of EAD by E4031 also supports the hypothesis that the 
IKs current was reduced by low-density plating because the similar observation was reported in 
cardiomyocytes obtained from dogs with chronic complete atrioventricular block (Volders et al., 
1998). 
Our analysis of ion channel expression revealed differences in gene expression between 
low- and high-density cell plating, as well as differences between hiPSC-derived cardiomyocytes 
and native human cardiac tissues. The difference between hiPSC-derived cardiomyocytes and 
human cardiac tissues may be caused by difference in the level of maturation, because hiPSC- and 
hESC-derived cardiomyocytes resemble fetal rather than adult cardiomyocytes in appearance, 
structure and function (Boheler et al., 2011; Ivashchenko et al., 2013). Another possible cause might 
be that the preparation of hiPSC-derived cardiomyocytes contains ventricular, atrial, nodal, and 
non-cardiac cells (Ma et al., 2011). Although the hiPSC-derived cardiomyocytes we used were 
purified to >97% cardiomyocytes by using selection methods based on the expression of 
cardiomyocyte-specific proteins and those with electrophysiological functions (Kattman et al., 
2011), the resulting cultures nonetheless included various types of cardiac cells, and the maturation 
level of our cultured cardiomyocytes was unknown. The types and levels of ion channels active in 
cardiac cells change according to the developmental stage and differ between nodal, atrial, and 
ventricular cells. We consider that these factors influenced the observed differences between 
hiPSC-derived cardiomyocytes and primary human cardiac cells. 
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The IKs current is carried by potassium channels formed by oligomeric association of 
subunits coded by KCNQ1 and KCNE1 (Sanguinetti et al., 1996). Another KCNE subunit, KCNE2, 
also associates with KCNQ1 subunit (Tinel et al., 2000). Mutations in KCNQ1, KCNE1 and KCNE2 
can lead to QT prolongation and are responsible for long QT syndrome types 1, 5 and 6, 
respectively (Abbott et al., 1999; Keating & Sanguinetti, 2001; Priori et al., 1999; Wang et al., 
1996). Inconsistent with the findings from the dog hypertrophy model (Ramakers et al. 2003), our 
study showed increased expression of KCNE1, the association subunit for IKs channels. Therefore, 
the contribution of the KCNE1 subunit for IKs in cardiac hypertrophy remains to be clarified. 
In previous studies of human adult hearts, KCNE2 gene expression was much lower than 
that of the KCNE1 gene, and KCNQ1 gene expression was much higher than that of the KCNE 
subunits (Bendahhou et al., 2005; Lundquist et al., 2005). On this point, the difference of expression 
levels between KCNQ1 and KCNE subunits were similar in our data, according to their threshold 
cycles (Ct) detected during qualitative PCR analysis (data not shown). Although the order of 
expression level is the same between hiPSC-derived cardiomyocytes and adult hearts, the 
interesting point is that expression of the KCNE2 gene was higher in the hiPSC-derived 
cardiomyocytes than in human hearts. Co-expression of KCNE2 with KCNQ1 can lead to the 
formation of potassium channels but decreases current amplitude and abolishes the voltage- and 
time-dependence of channel activation compared with those observed for KCNQ1 alone (Dedek & 
Waldegger, 2001; Tinel et al., 2000). However, owing to its high expression level, KCNE2 may 
contribute to basal potassium current in hiPSC-derived cardiomyocytes. Decreases in IK1 current 
also have been reported in dog models (Volders et al., 1999), and the observed reduction in KCNJ2 
gene expression in low-density cultured hiPSC-derived cardiomyocytes is compatible with this 
earlier finding. However, we did not confirm the expression level of KCNJ2 protein because of its 
likely low concentration, according to its Ct value during qualitative PCR analysis (data not shown). 
Because the changes in the expression levels of the potassium channel genes involved in the 
repolarization of cardiac action potentials that we noted in low-density cultured hiPSC-derived 
cardiomyocytes occurred in the same direction as those in reported hypertrophy models, our model 
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likely will be useful in studying electrical remodeling during hypertrophic conditions. 
Maturation of cardiomyocytes was not responsible for the observed alterations in gene 
expression, because the direction of changes in KCNQ1, KCNJ2 and KCNE1 were not mirrored in 
human fetal heart to adult heart. In addition, ATP2A2 expression is increased in the developing heart 
(Chen et al., 2000; Gombosova et al., 1998; Piquereau et al., 2010), whereas ATP2A2 expression 
was significantly lower in low-density cultured hiPSC-derived cardiomyocytes than in high-density 
cultured cells. Therefore, we conclude that the enlargement of hiPSC-derived cardiomyocytes 
represents a pathological hypertrophic phenomenon. 
We suggest that hiPSC-derived cardiomyocytes—under low-density plating conditions 
only—can be used as a tool to elucidate the mechanisms underlying cardiac hypertrophy. 
hiPSC-derived cardiomyocytes are devoid of proliferating fibroblasts and can be cultured for 
several weeks, during which they retain spontaneous beating. Because of these advantages, 
hypertrophy-associated phenomena can be observed by using diverse electrophysiological, cell 
biological, and molecular biological methods in small hiPSC-derived cardiomyocytes from soon 
after plating until long after the cells become enlarged (that is, hypertrophic). 
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Figure Captions 
 
Figure 1 
Images of enlarged hiPSC-derived cardiomyocytes (CMs) and hypertrophic features of 
cells plated at various densities. hiPSC-derived cardiomyocytes were plated at 90,000 cells/well 
(high density, 2813 cells/mm
2
) or 22,500 cells/well (low density, 703 cells/mm
2
) on 96-well plates, 
incubated for 7 days. (A) Cells were stained with an anti-plasma–membrane stain (red) and imaged 
under a confocal fluorescent microscope with a 63× objective. Upper and right panels show 
cross-sectional cell heights at lines shown on the center panels. Long and short scale bars are 50 and 
10 μm, respectively. (B) Cell areas were quantified. Horizontal bars in the plot show means ± SEM. 
Statistical significance was calculated by Welch’s t-test. *** P ≤ 0.001 (C) Cells were fixed with 
4% paraformaldehyde, stained with anti-α-actinin antibody (green), an anti-cytoplasm and 
anti-nucleus stain (red), and an anti-nucleic acid stain (blue) and processed for fluorescence 
microscopy with a 20× objective. Scale bar is 50 μm. (D) hiPSC-derived cardiomyocytes were 
plated at 5.3 × 10
5
 cells/well (high density, 2819 cells/mm
2
) or 98,000 cells/well (low density, 521 
cells/mm
2
) in 24-well plates and incubated for 7 days. Cells were trypsinized and counted under a 
microscope before lysis. The protein concentration of each whole-cell lysate was determined by 
using the BCA protein assay, and the protein content per cell was calculated. Values are expressed 
as means ± SEM. Statistical significance was evaluated by using Welch’s t-test. * P ≤ 0.05. 
 
Figure 2 
Expression levels of genes associated with cardiac hypertrophy in hiPSC-derived 
cardiomyocytes (CMs), as determined by quantitative PCR. hiPSC-derived cardiomyocytes were 
plated at 2.7 × 10
6
 cells/well (high density, 2813 cells/mm
2
; n = 3) or 0.5 × 10
6
 cells/well (low 
density, 521 cells/mm
2
; n = 3) in 6-well plates and lysed to extract total RNA at 7 days after plating. 
Gene expressions were analyzed by using cDNA derived from total RNA isolated from cells. (A) 
Expression levels of housekeeping genes, GAPDH, ACTB and 18S rRNA in hiPSC-derived 
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cardiomyocytes and human fetal and adult heart tissue (B) Amounts of NPPA, ATP2A2, ANKRD1, 
and MYL2 in hiPSC-derived cardiomyocytes were normalized relative to the expression level of 18S 
rRNA. Values are expressed as means ± SEM. Statistical significance was calculated by using 
Welch’s t-test. * P ≤ 0.05, ** P ≤ 0.01, and *** P ≤ 0.001. 
 
Figure 3 
Field-potential duration (FPD), inter-spike interval (ISI), and corrected FPD (FPDc) in 
hiPSC-derived cardiomyocytes plated at different densities. hiPSC-derived cardiomyocytes were 
plated at 30,000 cells/probe (very high density, 9554 cells/mm
2
), 15,000 cells/probe (high density, 
4777 cells/mm
2
), 7500 cells/probe (medium density, 2389 cells/mm
2
) or 3750 cells/probe (low 
density, 1194 cells/mm
2
). FPD and ISI were measured by using the MED64 system. FPDc was 
calculated according to Fridericia’s formula (FPDc = FPD/ISI1/3). Values are expressed as means ± 
SEM. Statistical significance was calculated by Welch’s t-test. * P ≤ 0.05, ** P ≤ 0.01, and *** P ≤ 
0.001 compared with values from very high density hiPSC-derived cardiomyocytes 
 
Figure 4 
Effects of IKs and IKr blockers on field potential duration (FPD) in hiPSC-derived 
cardiomyocytes plated at different densities. hiPSC-derived cardiomyocytes were plated at 30,000 
cells/probe (very high density, 9554 cells/mm
2
), 15,000 cells/probe (high density, 4777 cells/mm
2
), 
7500 cells/probe (medium density, 2389 cells/mm
2
) or 3750 cells/probe (low density, 1194 
cells/mm
2
). FPD and inter-spike interval (ISI) were measured by using the MED64 system after the 
cells had been treated with the IKs blockers chromanol 293B (n = 1–8) or HMR1556 (n = 3–10) or 
with the IKr blocker E-4031 (n = 3–9). A corrected FPD (FPDc) was calculated according to 
Fridericia’s formula (FPDc = FPD/ISI1/3). (A) All FPDc were normalized to represent the percentage 
of change from the baseline value. Values are expressed as means ± SEM. Statistical significance 
was calculated by the Jonckheere-Terpstra trend test. * P ≤ 0.05 and *** P ≤ 0.001 evaluated 
cell-density-dependent effects, and Welch’s t-test. # P ≤ 0.05, and ## P ≤ 0.01 compared with values 
from low density hiPSC-derived cardiomyocytes (3750 cells/probe) treated with E4031. (B) Typical 
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waveforms from low-density cells (3750 cells/probe) treated with DMSO as a baseline and those of 
early after depolarization (EAD) with 30 nM E4031 (arrows). EAD pattern was observed in 2 of 5 
cases. 
 
Figure 5 
Expression levels of genes associated with IKs channel subunits and of potassium channel-related 
genes in hiPSC-derived cardiomyocytes (CMs) and human fetal and adult heart tissue. (A) 
Quantitative PCR; hiPSC-derived cardiomyocytes were plated at 2.7 × 10
6
 cells/well (high density, 
2813 cells/mm
2
; n = 3) or 0.5 × 10
6
 cells/well (low density, 521 cells/mm
2
; n = 3) in 6-well plates 
and lysed to extract total RNA 7 days after plating. Amounts of KCNQ1, KCNE1, KCNE2, KCNH2 
and KCNJ2 were analyzed by using cDNA derived from total RNA isolated from cells. All data 
were normalized relative to the expression level of 18S rRNA. Values are expressed as means ± 
SEM. Statistical significance was calculated by Welch’s t-test. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 
0.001, and **** P ≤ 0.0001. (B) Western blotting. hiPSC-derived cardiomyocytes were plated at 5.3 
× 10
5
 cells/well (high density, 2819 cells/mm
2
; n = 4) or 98,000 cells/well (low density, 521 
cells/mm
2
; n = 3) on 24-well plates and lysed to extract protein 7 days after plating. Samples of 
lysate corresponding to 10 μg of protein samples were denatured and used to detect KCNQ1 and 
KCNH2. The typical pictures of KCNQ1 and KCNH2 bands are shown. Molecular weight markers 
are indicated on the left. The arrows on the right show the 2 types of glycosylated KCNH2 proteins. 
(C) Quantification of KCNQ1 and KCNH2 proteins bands in Western blot. Values are expressed as 
means ± SEM. Statistical significance was calculated by Welch’s t-test. * P ≤ 0.05. 
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Table 1 
Pathway analysis using DNA microarray data from low-density cultured hiPSC-derived 
cardiomyocytes to show overlaps in functional gene lists. 
Category   Function annotation   P 
Cardiac Hypertrophy   hypertrophy of heart chamber   0.000004 
Cardiac Hypertrophy   hypertrophy of heart   0.000006 
Cardiac Hypertrophy   hypertrophy of left ventricle   0.000007 
Cardiac Hypertrophy   ventricular hypertrophy   0.000009 
Cardiac Arteriopathy   coronary artery disease   0.000010 
Liver Hyperplasia/Hyperproliferation   liver cancer and tumors   0.000025 
Liver Hyperplasia/Hyperproliferation   liver cancer   0.000028 
Cardiac Necrosis/Cell Death   cell death of heart   0.000038 
Cardiac Dilation   dilation of heart ventricle   0.000237 
Cardiac Dilation   dilation of heart chamber   0.000295 
Listed are the top 10 of Tox Functions provided by using Ingenuity Pathway Analysis related 
to the lista of gene probes in low-density cultured hiPSC-derived cardiomyocytes with a fold 
change of ≥1.5 and a false discovery rate P-value of ≤0.05 compared with high-density 
cultured cells. Bold text indicates cardiac-hypertrophy–related pathway. P: P-value calculated 
by Fisher’s exact test. 
a hiPSC-derived cardiomyocytes were plated at a density of 2.7 × 106 cells/well (high density, 
2813 cells/mm2; n = 3) or 0.5 × 106 cells/well (low density, 521 cells/mm2; n = 3) in 6-well 
plates, incubated for 7 days, and lysed to extract total RNA. All gene expression data were 
normalized by using the quantile method. Expression changes are shown as fold changes 
compared with values in high-density cultured hiPSC-derived cardiomyocytes. Statistical 
significance was calculated by using Welch’s t-test, followed by adjustment for multiple 
comparisons by using a false discovery rate approach (Benjamini–Hochberg procedure). 
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